Concepts of pharmacotherapeutics, pharmacokinetics, pharmacodynamics

    1. Choose a pharmacological agent that has been on the market less than 5 years. 2. Research the literature and obtain two to three resources for current, evidence-based information related to the pharmacological agent. 3. Develop a teaching brochure and one page paper following these guidelines. a. Brochure for nurses- Focus on nurses for literacy level • Key/Relevant Drug Information (30 points/30%) o Drug Class o Mechanism of Action o Drug Administration and Dosage o Drug Interactions o Lab effects/interference • Patient Education Considerations (35 points/35%) o Nursing Management o Patient Education Considerations (special considerations)- provide examples specific to client age needs- geriatric, pediatric and pregnant client o Patient Assessment o Side Effects/Adverse Effects/Toxicities o Special considerations- provide examples specific to client age needs- geriatric, pediatric, and pregnant clients o Visual Effects/Creativity (10 points/10%) o Developed per the required standard o Appropriate for the intended audience (focus on nurses for literacy level) o Graphics enhance the purpose of the brochure o Brochure is visually appealing b. One Page Paper (15 points/15%) • Describes intended use of brochure (focus on nurses for literacy level) • Includes: o Name o Date o Class

Sample Solution

   

Teaching Brochure for Nurses

Key/Relevant Drug Information

  • Drug Class: Small interfering RNA (siRNA)
  • Mechanism of Action: Rivfloza is an siRNA that silences the lactate dehydrogenase A (LDHA) gene. LDHA is an enzyme that plays a role in the production of oxalate. By silencing the LDHA gene, Rivfloza reduces the production of oxalate and helps to prevent the formation of kidney stones.
  • Drug Administration and Dosage: Rivfloza is administered by intravenous infusion over 30 minutes every 3 months. The starting dose is 100 mg, and the dose may be increased to 300 mg if needed.

Full Answer Section

   
  • Drug Interactions: Rivfloza has not been studied extensively for drug interactions. However, it is important to be aware that Rivfloza is metabolized by the liver, so drugs that affect liver metabolism could potentially interact with Rivfloza.
  • Lab effects/interference: Rivfloza may interfere with laboratory tests that measure oxalate levels.
Patient Education Considerations
  • Nursing Management: Nurses should monitor patients for any signs or symptoms of adverse reactions, such as allergic reactions, infusion reactions, or liver toxicity. Nurses should also educate patients about the importance of adhering to their treatment schedule and of following up with their doctor regularly.
  • Patient Education Considerations (special considerations)- provide examples specific to client age needs- geriatric, pediatric, and pregnant clients:
    • Geriatric clients: Geriatric clients may be more susceptible to adverse reactions from Rivfloza, so nurses should monitor them closely.
    • Pediatric clients: Rivfloza has not been studied extensively in pediatric clients, so nurses should use caution when administering it to this population.
    • Pregnant clients: Rivfloza has not been studied in pregnant clients, so nurses should avoid administering it to this population.
  • Patient Assessment: Nurses should assess patients for any signs or symptoms of adverse reactions before, during, and after Rivfloza administration. Nurses should also monitor patients' vital signs and laboratory results regularly.
  • Side Effects/Adverse Effects/Toxicities: The most common side effects of Rivfloza are mild and go away on their own. These side effects may include headache, fatigue, nausea, and vomiting. More serious side effects, such as allergic reactions, infusion reactions, and liver toxicity, are rare.
  • Special considerations- provide examples specific to client age needs- geriatric, pediatric, and pregnant clients:
    • Geriatric clients: Geriatric clients may be more susceptible to adverse reactions from Rivfloza, so nurses should monitor them closely.
    • Pediatric clients: Rivfloza has not been studied extensively in pediatric clients, so nurses should use caution when administering it to this population.
    • Pregnant clients: Rivfloza has not been studied in pregnant clients, so nurses should avoid administering it to this population.
Visual Effects/Creativity The brochure should be visually appealing and easy to read. It should use simple language and avoid medical jargon. The brochure should also include graphics, such as charts or diagrams, to help explain the information. One Page Paper Intended Use of Brochure The teaching brochure is intended for nurses who care for patients with primary hyperoxaluria type 1. The brochure provides nurses with key information about Rivfloza, including its mechanism of action, administration and dosage, drug interactions, lab effects/interference, and patient education considerations. Conclusion Rivfloza is a new and innovative treatment for primary hyperoxaluria type 1. It is the first siRNA drug to be approved by the FDA. Rivfloza is a safe and effective treatment for primary hyperoxaluria type 1, and it can help to improve the quality of life for patients with this condition.  

IS IT YOUR FIRST TIME HERE? WELCOME

USE COUPON "11OFF" AND GET 11% OFF YOUR ORDERS